BioPhenyx

BioPhenyx minimize trial and error in drug discovery and use, offering better outcomes for pharma and patients, from the power of CRISPR-Select. CRISPR-Select can conclusively determine the potential role of any gene and gene-variants in disease development and - if relevant - how to most effectively target these. This include variants of essential genes, not possible before. This principle can profoundly impact how medicines, and other related biotechnology innovations, are developed and used. For Pharma R&D we may significantly positively impact outcomes of development programs, by early selection of disease relevant variants and deselection of non-relevant variants, and e.g. prove or disprove hypotheses generated or suggested by other technologies such as High Throughput Screening (HTS), Genome Wide Association Studies (GWAS), and/or Artificial Intelligence (AI). Technically we use our proprietary CRISPR-Select technology to tailor the "competition" for 1) "survival" or 2) selection of a specific trait, aka "phenotype", between two or more simultaneously CRISPR knocked-in gene-variants in a cell population. We grow the cell population for a few weeks under 1) selection pressure or 2) select for a relevant marker and then quantify the evolved difference between the gene-variants in the cell population. For quantification we use Polymerase Chain Reaction (PCR) and deep Next Generation Sequencing (NGS) of the pooled or "over-layered" variants. If there is no difference in quantity, the two or more variants will have the same (i.e. no) role in disease development. A large difference imply a large role in disease development. So far all known benign and pathogenic variants with known outcomes from ClinVar, measured with CRISPR-Select, correlates 100%. Consequently, CRISPR-Select is used by local hospitals, and work is ongoing to scale up the assay process.